Watchlist Price Alert

Spruce Biosciences Inc. (SPRB)

NASDAQ: SPRB · Real-Time Price · USD

0.07

0.00 (0.00%)

At close: May 09, 2025, 3:09 PM

0.07

0.00%

After-hours: May 09, 2025, 03:09 PM EDT

0.00% (1D)

Bid	0.07
Market Cap	3.02M
Revenue (ttm)	4.91M
Net Income (ttm)	-53.04M
EPS (ttm)	-1.29
PE Ratio (ttm)	-0.06
Forward PE	-0.11
Analyst	Hold

Ask	0.07
Volume	57,967
Avg. Volume (20D)	1,463,837
Open	0.07
Previous Close	0.07
Day's Range	0.07 - 0.07
52-Week Range	0.06 - 0.87
Beta	2.50

About SPRB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SPRB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SPRB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Spruce Biosciences has released their quartely earnings on May 6, 2025:

Revenue of $0 misses estimates by $500K, with -100.00% YoY decline.

EPS of -0.32 misses estimates by -0.12, with -14.29% YoY decline.

Why Price Moved

1 week ago

-39.14%

Spruce Biosciences shares are trading lower after ... Unlock content with Pro Subscription

3 weeks ago

-58.02%

Spruce Biosciences shares are trading lower. The company announced a new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B.

News

3 days ago · businesswire.com

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological di...

3 weeks ago · seekingalpha.com

Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)

Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medic...

3 weeks ago · businesswire.com

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...